Published in Pharmacology on January 01, 1982
Studies on the trigeminal antidromic vasodilatation and plasma extravasation in the rat. J Physiol (1984) 1.13
An examination of the pharmacology of two substance P antagonists and the evidence for tachykinin receptor subtypes. Br J Pharmacol (1986) 0.93
Contractile effects of substance P and other tachykinins on the mouse isolated distal colon. Br J Pharmacol (1989) 0.77
The mechanisms for tachykinin-induced contractions of the rabbit corpus cavernosum. Br J Pharmacol (2002) 0.76
Tetrazine-Containing Amino Acid for Peptide Modification and Live Cell Labeling. PLoS One (2015) 0.75
Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 8.11
Pharmacology of angiotensin. Pharmacol Rev (1974) 2.25
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci (1988) 1.83
Effects of peptides and non-peptides on isolated arterial smooth muscles: role of endothelium. Eur J Pharmacol (1985) 1.64
Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J (1990) 1.51
Selective agonists for substance P and neurokinin receptors. Neuropeptides (1987) 1.51
Pharmacological receptors for substance P and neurokinins. Life Sci (1987) 1.50
Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol (1992) 1.50
Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea. Br J Pharmacol (1988) 1.49
Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol (1983) 1.47
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
De novo formation of vascular receptors for bradykinin. Can J Physiol Pharmacol (1978) 1.45
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol (1966) 1.41
An analysis of the negative inotropic action of somatostatin. Br J Pharmacol (1979) 1.37
Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol (1977) 1.37
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
The actions of kinin antagonists on B1 and B2 receptor systems. Eur J Pharmacol (1986) 1.31
Competitive antagonists discriminate between NK2 tachykinin receptor subtypes. Br J Pharmacol (1990) 1.26
Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br J Pharmacol (1978) 1.24
Receptors for substance P. I. The pharmacological preparations. Eur J Pharmacol (1984) 1.24
Different receptors are involved in the endothelium-mediated relaxation and the smooth muscle contraction of the rabbit pulmonary artery in response to substance P and related neurokinins. Eur J Pharmacol (1986) 1.24
Relative potencies of neurokinins in guinea pig trachea and human bronchus. Eur J Pharmacol (1987) 1.22
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun (1992) 1.17
Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berl) (1999) 1.17
Characterization of neurokinin receptors in various isolated organs by the use of selective agonists. Life Sci (1987) 1.14
Studies on the trigeminal antidromic vasodilatation and plasma extravasation in the rat. J Physiol (1984) 1.13
Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol (2001) 1.12
Selectivity and specificity of new, non-peptide, quinuclidine antagonists of substance P. Biochem Biophys Res Commun (1991) 1.10
Biological activity of N-terminal fragments of calcitonin gene-related peptide. Eur J Pharmacol (1990) 1.10
Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J Cardiovasc Pharmacol (1984) 1.10
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.08
The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. Eur J Pharmacol (1987) 1.08
Cardiovascular actions of kinins in the rabbit. Can J Physiol Pharmacol (1979) 1.08
BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol (2000) 1.08
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol (1998) 1.07
Receptors for kinins in isolated arterial vessels of dogs. Eur J Pharmacol (1989) 1.07
Peptides and the human colon: an in vitro pharmacological study. Can J Physiol Pharmacol (1981) 1.05
Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension (1998) 1.05
Kinin receptors in experimental inflammation. Can J Physiol Pharmacol (1980) 1.05
Bradykinin analogue blocks bradykinin-induced inhibition of a spinal nociceptive reflex in the rat. Eur J Pharmacol (1987) 1.03
Histamine release and local responses of rat and human skin to substance P and other mammalian tachykinins. Pharmacology (1986) 1.03
Pressor action of beta blocking agents in rats. Can J Physiol Pharmacol (1970) 1.03
Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis (1989) 1.03
Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors. J Auton Pharmacol (1987) 1.02
Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema. Peptides (1996) 1.02
Nociceptin/orphanin FQ receptor ligands. Peptides (2000) 1.02
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem (1998) 1.02
Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther (1990) 1.01
Structure-activity studies of neurokinin A. Neuropeptides (1989) 1.01
Nonadrenergic and noncholinergic arterial dilatation and venoconstriction are mediated by calcitonin gene-related peptide1 and neurokinin-1 receptors, respectively, in the mesenteric vasculature of the rat after perivascular nerve stimulation. J Pharmacol Exp Ther (1992) 1.01
The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol (1996) 1.00
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.00
Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. J Med Chem (2000) 1.00
A highly selective NK-2 tachykinin receptor antagonist containing D-tryptophan. Eur J Pharmacol (1990) 0.99
Structure-activity studies of bradykinin and related peptides. B2-receptor antagonists. Hypertension (1991) 0.99
Permeability of endothelial monolayers to albumin is increased by bradykinin and inhibited by prostaglandins. Am J Physiol Lung Cell Mol Physiol (2001) 0.99
Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg (1998) 0.98
Structure-activity studies of B1 receptor-related peptides. Antagonists. Hypertension (1996) 0.97
Site of action of angiotensin and other vasoconstrictors on the kidney. Can J Physiol Pharmacol (1971) 0.97
The stimulatory effects of neurotensin and related peptides in rat stomach strips and guinea-pig atria. Br J Pharmacol (1980) 0.97
Peptides and histamine release from rat peritoneal mast cells. Eur J Pharmacol (1985) 0.97
Effect of synthetic tachykinin analogues on airway microvascular leakage in rats and guinea-pigs: evidence for the involvement of NK-1 receptors. J Auton Pharmacol (1991) 0.97
Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol (1993) 0.96
Specific agonists for neurokinin B receptors. Eur J Pharmacol (1987) 0.96
Prerequisites for the natriuretic effect of val-5-angiotensin II amide in the rat. Am J Physiol (1968) 0.96
Antagonists for the neurokinin NK-3 receptor evaluated in selective receptor systems. Regul Pept (1990) 0.96
Interleukin-6 secretion from human astrocytoma cells induced by substance P. J Neuroimmunol (1994) 0.96
Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol (2000) 0.96
LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther (1997) 0.95
Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides (1994) 0.95
Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors. Br J Pharmacol (2008) 0.95
The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol (1999) 0.94
Conversion of kinins and their antagonists into B1 receptor activators and blockers in isolated vessels. Eur J Pharmacol (1986) 0.94
Hepoxilin A3 increases vascular permeability in the rat skin. Eicosanoids (1991) 0.94
Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.94
Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur J Pharmacol (1997) 0.94
Antagonists of angiotensin. Substitution of an aliphatic chain to phenyl ring in position 8. Rev Can Biol (1971) 0.94
Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist. Psychopharmacology (Berl) (2000) 0.94
Pharmacological characterization of the vascular permeability enhancing effects of kinins in the rabbit skin. Can J Physiol Pharmacol (1981) 0.93
Pharmacological studies of kinins in venous smooth muscles. Can J Physiol Pharmacol (1981) 0.93
Receptors for bradykinin in intestinal and uterine smooth muscle. Can J Physiol Pharmacol (1977) 0.93
Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am J Physiol (1996) 0.93
Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.93
Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol (1993) 0.93
Role of the C-terminal group for the biological activities of angiotensin. Can J Physiol Pharmacol (1975) 0.92
Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat. Br J Pharmacol (1992) 0.92
Neurokinin receptors in the rat lower urinary tract. J Pharmacol Exp Ther (1988) 0.92
Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. Br J Pharmacol (1994) 0.92
DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension (1991) 0.92
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci (2003) 0.92
Intrathecal bradykinin acts presynaptically on spinal noradrenergic terminals to produce antinociception in the rat. Eur J Pharmacol (1989) 0.92
Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides (2007) 0.91